Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721. (Q43440895)

23 November 2017

title

Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721. (English)

1 reference

23 November 2017

Hirschel-Scholz S

1

1 reference

23 November 2017

Charhon S

2

1 reference

23 November 2017

Rizzoli R

3

1 reference

23 November 2017

Caverzasio J

4

1 reference

23 November 2017

Paunier L

5

1 reference

23 November 2017

Bonjour JP

6

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 May 1988

1 reference

23 November 2017

1 reference

23 November 2017

volume

33

1 reference

23 November 2017

issue

5

1 reference

23 November 2017

page(s)

934-941

1 reference

Calcification in end-stage kidneys

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Prevention of Phosphate-induced Nephrocalcinosis by Parathyroidectomy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Effect of Parathyroid Hormone on Osmotic Fragility of Human Erythrocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Effect of parathyroid hormone on rat heart cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Toxicity of parathyroid hormone in uremia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Prevention of parathyroid hormone-dependent nephrocalcinosis by chronic administration of the organic phosphorothioate WR-2721

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Parathyroid hormone-independent adaptation of the renal handling of phosphate in response to renal mass reduction

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

The effects in the rat of varying intakes of dietary calcium, phosphorus, and hydrogen ion on hyperparathyroidism due to chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Preservation of function in experimental renal disease by dietary restriction of phosphate

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Direct and indirect measurements of osteoid seam width in human iliac crest trabecular bone

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Effects of parathyroidectomy on bone formation and mineralization in hemodialyzed patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Effect of various protein diets on growth, renal function, and survival of uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Protective drugs in cancer therapy: Optimal clinical testing and future directions

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Protective effect of intrarenal calcium membrane blockers before or after renal ischemia. Functional, morphological, and mitochondrial studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Calcium and ischemic injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Verapamil protects against progression of experimental chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1988.90

7 January 2021

Identifiers

DOI

10.1038/KI.1988.90

1 reference

23 November 2017

1 reference